Stock Update (NASDAQ:CYTK): Cytokinetics, Inc. Announces Results From COSMIC-HF to be Presented in Late Breaking Clinical Trial Session at AHA Scientific Sessions

Cytokinetics, Inc. (NASDAQ:CYTK) announced that results from the expansion phase of COSMIC-HF (ChronicOral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluatingomecamtiv mecarbil in patients with chronic heart failure, will be presented in the Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions 2015 on November 8 in Orlando, FL.

Clinical Presentation:

Date: Sunday, November 8, 2015

Session Time: 3:45-5:00 p.m. ET (Hall D)

Presentation Time: 4:31-4:40 p.m. ET

Session: LBCT.01 Failure is Not an Option: New Drugs and Systems of Care

Presentation Title: Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): Final Results from a Double-blind, Randomized, Placebo-controlled, Multicenter Study

Investor Event:

The Company will host an investor meeting and Webcast the following day, Monday, November 9, 2015 from 7:00 AM – 8:00 AM ET in Salon 10 of the Rosen Center. (Original Source)

Shares of Cytokinetics closed yesterday at $10.36. CYTK has a 1-year high of $10.75 and a 1-year low of $3.98. The stock’s 50-day moving average is $7.45 and its 200-day moving average is $6.83.

On the ratings front, Cytokinetics has been the subject of a number of recent research reports. In a report issued on October 23, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on CYTK, with a price target of $18, which implies an upside of 73.7% from current levels. Separately, on September 15, FBR’s Vernon Bernardino reiterated a Buy rating on the stock and has a price target of $14.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joseph Pantginis and Vernon Bernardino have a total average return of -4.2% and -18.8% respectively. Pantginis has a success rate of 37.2% and is ranked #3730 out of 3827 analysts, while Bernardino has a success rate of 25.9% and is ranked #3800.

Cytokinetics Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts